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Patients coinfected with hepatitis C virus (HCV) and human 
immunodeficiency virus (HIV) are at high risk of liver disease 
progression. We report a favorable safety profile and SVR12 
rates of 96.7% among HIV/HCV coinfected patients partici-
pating in an Italian compassionate-use program of ombitasvir/
paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± riba-
virin (RBV).
Keywords. HIV/HCV coinfection; DAA; IFN-free; antivi-
ral therapy; anti-HCV therapy.
Worldwide, an estimated 5–10 million individuals with human 
immunodeficiency virus (HIV) are coinfected with hepatitis C 
virus (HCV) [1]. In Italy, approximately 30% of HIV-infected 
patients are coinfected with HCV, leading to an estimated 
60 000 HIV/HCV coinfected individuals [2]. Coinfection nega-
tively impacts the progression of HCV in several ways, includ-
ing enhanced rates of HCV replication, decreased rates of HCV 
clearance, and increased fibrosis and hepatic decompensation 
[3]. Moreover, HIV-infected patients on antiretroviral ther-
apy (ART) regimens with HCV-related liver disease have an 
increased risk of all-cause and liver-related mortality compared 
with HIV-negative individuals [4].
HCV virologic cure in HIV-coinfected patients reduces the 
risk of liver-related outcomes [5]. However, treatment with 
pegylated interferon (pegIFN) and ribavirin (RBV) yielded 
poor sustained virologic response (SVR) rates [5]. In Europe, 
there are several interferon (IFN)-free direct-acting antivi-
ral (DAA) regimens approved for the treatment of HIV/HCV 
GT1 coinfected patients. In clinical studies, the all-oral, 3-DAA 
regimen of ombitasvir, paritaprevir, with the pharmacokinetic 
enhancer ritonavir, and dasabuvir (OBV/PTV/r + DSV) + RBV 
administered for 12 or 24 weeks has achieved SVR at week 12 
post-treatment (SVR12) rates between 91% and 100% in HIV/
HCV coinfected patients [6, 7]. With high rates of virologic 
response achieved with OBV/PTV/r  +  DSV  +  RBV in this 
patient population in clinical trials, it is increasingly important 
to evaluate this regimen in the real world.
Compassionate-use programs for DAAs give high-pri-
ority patients preapproval access to treatment and provide 
important data on safety and effectiveness in the real world. 
Here, we present data on the safety and effectiveness of OBV/
PTV/r + DSV ± RBV in HIV/HCV GT1-infected patients who 
participated in a compassionate-use program coordinated by 
the Italian Society of Infectious and Tropical Diseases (SIMIT).
METHODS
Patients
The compassionate-use program provided access to treatment 
for patients with HCV GT1 or GT4 infection with or with-
out compensated cirrhosis, including patients coinfected with 
HIV. The program enrolled 213 patients; 210 HCV GT1/HIV 
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coinfected patients who completed 12 weeks of follow-up were 
evaluated in this analysis. All eligible patients were either treat-
ment-naive or pegIFN/RBV-experienced, with or without cir-
rhosis, and were receiving a stable ART regimen (Supplementary 
Table 1).
Study Design
HCV GT1-infected patients were enrolled at 26 sites through-
out Italy and received once-daily, coformulated OBV/PTV/r 
(25/150/100  mg) and twice-daily DSV (250  mg) plus RBV. 
Patients with cirrhosis received 24 weeks of treatment and 
those without received 12 weeks of treatment. HCV GT1b-
infected patients without cirrhosis received OBV/PTV/r + DSV 
for 12 weeks, whereas those with cirrhosis received OBV/
PTV/r  +  DSV  +  RBV for 24 weeks. RBV was administered 
twice-daily according to body weight and label recommenda-
tions [8]. Patients receiving a ritonavir-boosted ART regimen 
discontinued the ritonavir component of their ART regimen as 
recommended by the local OBV/PTV/r + DSV label [9, 10].
All patients in the study provided written informed con-
sent, and the study was conducted in accordance with the 
International Conference on Harmonization guidelines, appli-
cable regulations, and the principles of the Declaration of 
Helsinki. All authors had access to the study data and reviewed 
and provided feedback on all subsequent versions of the man-
uscript and made the decision to submit the manuscript for 
publication.
Study Assessments
Investigators performed laboratory testing, patient visits and 
follow-up according to the sites’ local standards, whereas safety 
and effectiveness assessments were performed at the discretion 
of the investigators. Because this was a compassionate-use pro-
gram in a real-world setting, missing laboratory assessments 
were permitted.
The primary endpoint for effectiveness was the percentage of 
patients achieving SVR12 (HCV RNA <25 IU/mL [lower limit 
of quantitation, LLOQ]). HCV RNA testing was performed 
by each site’s local laboratory. Secondary analyses included 
the percentage of patients with on-treatment virologic failure 
(breakthrough, defined as a confirmed HCV RNA level ≥25 IU/
mL after achieving HCV RNA <25 IU/mL) or post-treatment 
relapse (defined as a confirmed HCV RNA level ≥25  IU/mL 
during the post-treatment follow-up window in patients who 
had HCV RNA below the LLOQ at the end of treatment).
Data on AE severity and relation to study drugs were col-
lected by physicians, reported in the databases, and communi-
cated to investigators throughout the study.
Statistical Analysis
Analyses for effectiveness were performed in the intent-to-treat 
(ITT) population, defined as all enrolled patients that received 
at least 1 dose of study drug. Analyses were performed using 
Epi Info™, a public domain suite of interoperable software tools 
designed by the Centers for Disease Control and Prevention 
(CDC).
RESULTS
Patients
Two-hundred and thirteen HCV GT1-infected patients with 
HIV/HCV coinfection were enrolled. In total, 210 patients 
completed 12 weeks of follow-up and were included in the anal-
ysis (HCV RNA was undetectable at end of treatment in the 3 
enrolled patients that were not included in the current analysis). 
The ITT population comprised 74.8% males and 98.6% white 
race; 11.0% had liver stiffness of >12.5  kPa (F4), 66.2% were 
infected with HCV GT1a. Complete baseline demographics are 
presented in Supplementary Table 1.
Effectiveness
HCV RNA suppression was rapid in HIV/HCV coinfected 
patients; 85.1% of patients with data available had HCV RNA 
levels below LLOQ at treatment week 4, by the end of treat-
ment 98.6% of patients reached SVR. The overall SVR12 rate 
was 96.7% (203/210). Percentages of patients with HCV RNA 
levels below the LLOQ during treatment, at end of treatment, 
and post-treatment are presented in Figure  1. GT1 subtype, 
presence of cirrhosis, prior treatment history, baseline plate-
let count, CD4+ count, and HIV viral load had no impact on 
SVR12 rates. SVR12 rates were significantly higher (P  =  .01) 
among patients with baseline HCV RNA <1 000 000  IU/mL 
versus those with HCV RNA ≥1 000 000 IU/mL.
Seven patients did not achieve SVR12; 6 experienced viro-
logic failure, and 1 prematurely discontinued treatment at week 
6.  Four GT1b-infected patients experienced virologic fail-
ure; 2 experienced virologic breakthrough between treatment 
weeks 8 and 12, and 2 relapsed between end of treatment and 
post-treatment week 12. Upon retesting, 1 patient who relapsed 
was found to be infected with HCV GT3a. Two GT1a-infected 
patients relapsed between end of treatment and post-treatment 
week 12. Disease and virologic characteristics of patients that 
experienced virologic failure are presented in Supplementary 
Table 2.
Impact of OBV/PTV/r + DSV ± RBV Treatment on Liver Function
Compared with baseline, mean AST, ALT, and hemoglobin were 
significantly lower at end of OBV/PTV/r + DSV ± RBV treat-
ment (P < .001), whereas mean platelet count and total bilirubin 
were significantly higher (P < .001) (Supplementary Figure 1).
Maintenance of HIV-1 Suppression and Immunologic Response
Before enrollment, 121 patients (57.6%) modified their ART 
regimen. Compared with baseline, there were no signifi-
cant (P  >  .05) changes at end of treatment in the proportion 
of patients with HIV RNA <50  copies/mL, mean CD4+ cell 
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counts, proportion of CD4+ cells, or CD4+ /CD8+ ratio 
(Supplementary Figure  2). Complete information on baseline 
ART regimen is presented in Supplementary Table 1.
Safety
Treatment-emergent AEs occurred in 88 (41.9%) patients. One 
(0.5%) patient experienced a serious AE (hospitalization due to 
a cardiac episode); which was not considered related to study 
drugs. This patient continued treatment and achieved an SVR12. 
No patient experienced an AE leading to discontinuation of study 
drugs, and no deaths were reported (Supplementary Table 3).
DISCUSSION
In this compassionate-use program, patients with HIV/HCV GT1 
coinfection treated with OBV/PTV/r + DSV ± RBV for 12 or 24 
weeks achieved an SVR12 rate of 96.7%, similar to SVR12 rates 
reported in clinical trials [6, 7]. Of the patient subgroups analyzed, 
only baseline HCV viral load had an impact on SVR12 rates. 
Markers of liver function, including ALT, AST, and platelet count, 
significantly improved at end of treatment compared with base-
line, suggesting that treatment with OBV/PTV/r + DSV ± RBV is 
associated with normalization of liver function.
In this study, 57.6% of patients modified their ART regi-
men at start of OBV/PTV/r + DSV ± RBV treatment; however, 
change of ART treatment had no impact on the proportion of 
patients with undetectable HIV RNA or on CD4+ parameters at 
end of OBV/PTV/r + DSV ± RBV treatment.
OBV/PTV/r + DSV ± RBV was generally well tolerated, with 
no patient discontinuing treatment due to an AE. Compared with 
baseline, mean hemoglobin was significantly (P < .001) lower at 
end of treatment, whereas mean total bilirubin was significantly 
(P < .001) higher at end of treatment; however, these changes 
were not considered to be clinically relevant. Increases in bil-
irubin levels reported here are consistent with those described 
in previous safety analyses of OBV/PTV/r + DSV ± RBV [11]. 
Increases in bilirubin levels reported in previous analyses were 
self-resolving, predominately indirect, and related to the inhi-
bition of the bilirubin transporters OATP1B1/1B3 by PTV and 
to RBV-induced hemolysis [18], not due to OBV/PTV/r + DSV 
hepatotoxicity.
In conclusion, our findings suggest that OBV/PTV/r  +   
DSV ± RBV is safe and effective in compassionate-access pro-
grams for patients with HCV genotype 1 infection and HIV 
coinfection, a high-priority patient population.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
Figure 1. HCV RNA < 25 IU/mL during treatment with OBV/PTV/r + DSV ± RBV, at 4 weeks and end of treatment, and at post-treatment weeks 4 and 12. A, HCV RNA <25 IU/
mL during treatment. B, SVR12 rates by baseline genotype, cirrhosis status, prior treatment history, and platelet count. C, SVR12 rates by CD4+ count, HIV viral load, and base-
line HCV RNA. Abbreviations: DSV, dasabuvir; HCV, hepatitis C virus; HIV, human immunodeficiency virus; OBV, ombitasvir; RBV, ribavirin; SVR, sustained virologic response.
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so questions or comments should be addressed to the corresponding 
author.
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